Context Therapeutics Inc. — Director's Dealing 2023

Feb 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Context Therapeutics Inc. (CNTX)
CIK: 0001842952
Period of Report: 2023-02-13

Reporting Person: Minai-Azary Jennifer Lynn (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-13	Stock Option (right to buy)	$0.8407	A	158001	Acquired	2033-02-12	Common Stock (158001.0)	Direct

Footnotes

F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2024, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.